Literature DB >> 15203087

Janet Woodcock discusses the FDA and the drug development process. Interview by Christopher Watson.

Janet Woodcock1.   

Abstract

Currently Acting Deputy Commissioner for Operations at FDA, Janet Woodcock has served as Director, Center for Drug Evaluation and Research at FDA since 1994. She previously served in other positions in FDA including Director, Office of Therapeutics Research and Review and Acting Deputy Director, Center for Biologics Evaluation and Research. She received her MD from Northwestern Medical School and held faculty appointments at the Pennsylvania State University and the University of California in San Francisco. She joined FDA in 1986.

Mesh:

Year:  2004        PMID: 15203087     DOI: 10.1016/S1359-6446(04)03160-5

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  2 in total

1.  Deficiencies in the reporting of VD and t(1/2) in the FDA approved chemotherapy drug inserts.

Authors:  Malcolm J D'Souza; Ghada J Alabed
Journal:  Pharm Rev       Date:  2010-02-03

2.  A novel hybrid framework for metabolic pathways prediction based on the graph attention network.

Authors:  Zhihui Yang; Juan Liu; Hayat Ali Shah; Jing Feng
Journal:  BMC Bioinformatics       Date:  2022-09-28       Impact factor: 3.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.